
<!DOCTYPE html>
<html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#">
  
<!-- Mirrored from investors.scholarrock.com/node/7531/html by HTTrack Website Copier/3.x [XR&CO'2014], Sat, 21 Dec 2024 12:11:37 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=UTF-8" /><!-- /Added by HTTrack -->
<head>
    <title>SEC Filing - Scholar Rock, Inc.</title>
    <meta name="robots" content="noindex">
    <link rel="stylesheet" media="all" href="../../sites/g/files/knoqqb56236/files/css/css_-Ogun-b4Vwq8nD6qwBoEYuBhEF_0grnAaUrH4akFvLUcd37.css?delta=0&amp;language=en&amp;theme=nir_pid2662&amp;include=eJyNjEEKgDAMBD8k9UkhTQMGSiJNRfp7ayuePHjK7jAblQIRnVdnAq8tsy_a2cnRpTKoVSH29YOF5w5__LiDkOlEqJhbN-b4bQGTRYaMh9L2Q9yLpQuf0kIl" />

    
    <!-- IrwinIQ Tag Manager --> <script> (function(w,d){ var _mtm = w._mtm = w._mtm || []; _mtm.push({'mtm.startTime': (new Date().getTime()), 'event': 'mtm.Start'}); var g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true; g.src='../../../analytics.imirwin.com/js/container_XFyWYf0m.js'; s.parentNode.insertBefore(g,s); })(window, document); </script> <!-- End IrwinIQ Tag Manager -->

<!-- Google Tag Manager -->
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'../../../www.googletagmanager.com/gtm5445.html?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-WTGMF33');</script>
<!-- End Google Tag Manager -->

<!-- Google Tag Manager (noscript) -->
<noscript><iframe src="../../../www.googletagmanager.com/nsca0c.html?id=GTM-WTGMF33"
height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<!-- End Google Tag Manager (noscript) -->
  </head>
  <body class="body-sidebars-first nir-node nir-node--type-nir-sec-filing nir-node--7531 page-template-default page page-parent wp-custom-logo wp-embed-responsive full-width-content genesis-breadcrumbs-visible genesis-singular-image-hidden genesis-footer-widgets-visible top-parent-investors-media investors-media has-no-blocks elementor-default elementor-page cbp-spmenu-push cookies-set cookies-accepted body_classes" id="body" cz-shortcut-listen="true">
      <div class="region region-content">
    <div id="block-nir-pid2662-websitenoticeblock" class="block--website-notice-block block--website-notice-block--7531 block--content--website-notice-block block--content--website-notice-block--7531 block--24a64b1d-13aa-4b20-8029-2df59f99a96c block--24a64b1d-13aa-4b20-8029-2df59f99a96c--7531 block block-nir-website-notices block-website-notice-block">
  
    
      
  </div>
<div data-drupal-messages-fallback class="hidden"></div>

<div id="block-nir-pid2662-content" class="block--system-main-block block--system-main-block--7531 block--content--system-main-block block--content--system-main-block--7531 block--c4d2f333-a7f8-46c4-afc3-3e36992b73c0 block--c4d2f333-a7f8-46c4-afc3-3e36992b73c0--7531 block block-system block-system-main-block">
  
    
      <div class="nir-sec-header"><div class="logo"><img src="../../sites/g/files/knoqqb56236/files/Logo.png" alt="Scholar Rock, Inc." />
</div><div class="sec-docs">View:  <div class="file-link">
  <span class="file file--mime-application-rtf file--general"> <a href="../../static-files/0001157523-20-001161.rtf%3b%20filename_%3dUTF-8%27%270001157523-20-001161.rtf" type="application/rtf" title="0001157523-20-001161.rtf">Download DOC</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="../../static-files/0001157523-20-001161.pdf%3b%20filename_%3dUTF-8%27%270001157523-20-001161.pdf" type="application/pdf" title="0001157523-20-001161.pdf">Download PDF</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-vnd-ms-excel file--x-office-spreadsheet"> <a href="../../static-files/0001157523-20-001161.xls%3b%20filename_%3dUTF-8%27%270001157523-20-001161.xls" type="application/vnd.ms-excel" title="0001157523-20-001161.xls">Download XLS</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-octet-stream file--general"> <a href="../../sec-filings/sec-filing/8-k/0001157523-20-001161.html" type="application/octet-stream" title="0001157523-20-001161-ex-101-sch---xbrl-taxonomy-extension-schema.xsd">Download XBRL</a></span><span class="filesize"> </span>
</div>
</div></div>
    <XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:srrk="http://scholarrock.com/20200806" xmlns="../../../www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 7.0.1.0
         Copyright 1995 - 2020 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_6a38e8e0679c4f878545f82646c44ef5" contextRef="c20200806to20200806" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_dbbf6f1e8bca40aa9a67fd01ad6cbb09" contextRef="c20200806to20200806">0001727196</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="#srrk-20200806.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20200806to20200806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-06</xbrli:startDate><xbrli:endDate>2020-08-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div>
    <div>
      <div style="text-align: center;"><span style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;">UNITED


          STATES</span><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
          SECURITIES AND EXCHANGE COMMISSION</span><br />
        <span style="font-weight: bold;">Washington, D.C. 20549</span><br />
        _____________________</div>

      <div>&#160;</div>

      <div style="text-align: center;"><span style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;">FORM


          <ix:nonNumeric name="dei:DocumentType" id="Fact_09f893ac65b64bd2af919812d86dc10f" contextRef="c20200806to20200806">8-K</ix:nonNumeric></span><br />
        _____________________</div>

      <div>&#160;</div>

      <div style="text-align: center; font-weight: bold;">CURRENT REPORT</div>

      <div>&#160;</div>

      <div style="text-align: center; font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>

      <div>&#160;</div>

      <div style="text-align: center;">Date of Report (Date of earliest event Reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_64826db5d9994bcdb0f91e3d42e185ff" contextRef="c20200806to20200806" format="ixt:datemonthdayyearen">August 6, 2020</ix:nonNumeric></div>

      <div>&#160;</div>

      <div style="text-align: center;"><span style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_cdf22c7e9e9e4a5b98583a7a4a92178a" contextRef="c20200806to20200806">Scholar Rock Holding Corp</ix:nonNumeric>oration</span><br />
        (Exact Name of Registrant as Specified in Charter)</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" id="z107cf8ce03914b7f865c0dfc5f27fdba" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_133f6767a4334c3493656a9acf99f21b" contextRef="c20200806to20200806" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_95b56c66f72448a9a4b024dcb0f7375c" contextRef="c20200806to20200806">001-38501</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_530618c7a58c41f2bc8c7db5a7706a40" contextRef="c20200806to20200806">82-3750435</ix:nonNumeric><br />
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center;">(State or Other Jurisdiction of Incorporation)</div>
            </td>

    <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center;">(Commission File Number)</div>
            </td>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center;">(I.R.S. Employer Identification Number)</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-align: center;"><span style="font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_e2fdab5df4d24497997d3099e547e554" contextRef="c20200806to20200806">620 Memorial Drive</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_54ada3a24048475fa8ee86a653089dfd" contextRef="c20200806to20200806">2nd Floor</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_80d4ab5dc642408ea1c3d363d544bb33" contextRef="c20200806to20200806">Cambridge</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_065e36a834994ad893301f7d28fa6d04" contextRef="c20200806to20200806">MA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_2c3e06425b5245b5936bada4cb19b8b9" contextRef="c20200806to20200806">02139</ix:nonNumeric></span><br />
        (Address of Principal Executive Offices) (Zip Code)</div>

      <div>&#160;</div>

      <div style="text-align: center;"><span style="font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_ea4a5ac3f0354070b74903b2fb1e00d6" contextRef="c20200806to20200806">857</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_1c6cd6dfe0484ac489a528cb833ecc83" contextRef="c20200806to20200806">259-3860</ix:nonNumeric></span><br />
        (Registrant&#8217;s telephone number, including area code)</div>

      <div>&#160;</div>

      <div style="text-align: center;">(Former name or former address, if changed since last report)</div>

      <div>&#160;</div>

      <div>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

      <div>&#160;</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_52f6e2889ea94cedb0a8159a3a627079" contextRef="c20200806to20200806" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span style="text-indent: 0px; font-size: 6pt;">&#160; </span>Written



        communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_62a24276469d467c9a2d7695d3efe004" contextRef="c20200806to20200806" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span style="text-indent: 0px; font-size: 6pt;">&#160; </span>Soliciting



        material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_6526f82ce8d348818105809a884b346b" contextRef="c20200806to20200806" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span style="text-indent: 0px; font-size: 6pt;">&#160; </span>Pre-commencement



        communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_eb644e9521f7462c80a2bcdcb8ba837a" contextRef="c20200806to20200806" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span style="text-indent: 0px; font-size: 6pt;">&#160; </span>Pre-commencement



        communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>

      <div>&#160;</div>

      <div>Securities registered pursuant to Section 12(b) of the Act:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" id="z70d7d1ffb9404515954838ce95d0dafe" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 39.56%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: center; font-weight: bold;">Title of each class</div>
            </td>

    <td style="width: 22%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Trading Symbol(s)</div>
            </td>

    <td style="width: 38%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Name of each exchange on which registered</div>
            </td>

  </tr>

  <tr>

    <td style="width: 39.56%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: center;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_6746e1df272d45149f13609973c0f4a7" contextRef="c20200806to20200806">Common Stock, par value $0.001 per share</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 22%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_79668de9e0554c8faef76ac262f469ea" contextRef="c20200806to20200806">SRRK</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 38%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_daa64774cac54424ba60cc92a568b361" contextRef="c20200806to20200806" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric><br />
              </div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div>&#160;</div>

      <div>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule&#160;12b-2&#160;of the Securities Exchange Act of 1934 (17 CFR&#160;&#167;240.12b-2).&#160;Emerging growth company
        <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_150aeedcaf754a0892d450adefbeecdf" contextRef="c20200806to20200806" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric></div>

      <div>&#160;</div>

      <div>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
        Act. <ix:nonNumeric name="dei:EntityExTransitionPeriod" id="Fact_ff8bee4323f64a47861c7acc5c276969" contextRef="c20200806to20200806" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric></div>

      <div>&#160;</div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      </div>

      <div style="font-weight: bold;"> <br />
      </div>

      <div style="font-weight: normal;">
        <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 2.02. Results of Operations and Financial Condition.</div>

        <div><br />
        </div>

        <div style="background-color: #FFFFFF;">
          <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On August 7, 2020, Scholar Rock Holding Corporation (the &#8220;Company&#8221;) issued a press release announcing its financial
            and operating results for the quarter ended June 30, 2020. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.</div>

          <div><br />
          </div>

          <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company will host a live conference call and webcast at 8:00am ET on Friday, August 7, 2020 to discuss second
            quarter 2020 financial results and business progress, as well as provide an introduction to the newest members of its management team. Participating on the call will be Tony Kingsley (President and CEO), Ted Myles (CFO and Head of Business
            Operations), and Yung Chyung (Chief Medical Officer). A copy of the slide deck that will be presented&#160; during the conference call and webcast is being furnished as Exhibit 99.2 to this Report on Form 8-K. A live webcast of the conference call
            may be accessed by visiting the Investors &amp; Media section of the Company&#8217;s website at http://investors.scholarrock.com.</div>

          <div><br />
          </div>

        </div>

        <div style="background-color: #FFFFFF;">
          <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-indent: 36pt;">The information in this Report on Form 8-K and Exhibits 99.1 and 99.2 attached hereto is intended to be furnished
            and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any
            filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</div>

        </div>

        <div><br />
        </div>

        <div><br />
        </div>

        <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 9.01. Financial Statements and Exhibits.</div>

        <div>&#160;</div>

        <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d) Exhibits</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z5f1d3c63413a47aab1b1891b4b5a9a7c">


  <tr>

    <td style="width: 9.07%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Exhibit</div>
                <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">No.</div>
              </td>

    <td style="width: 1%; vertical-align: middle; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td style="width: 90%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9.07%; vertical-align: middle;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 1%; vertical-align: middle;" colspan="1">&#160;</td>

    <td style="width: 90%; vertical-align: middle;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9.07%; vertical-align: middle;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#a52262995ex99_1.htm">99.1</a></div>
              </td>

    <td style="width: 1%; vertical-align: middle;" colspan="1">&#160;</td>

    <td style="width: 90%; vertical-align: middle;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#a52262995ex99_1.htm">Press Release issued
                    by the Company on August 7, 2020, furnished hereto.</a></div>
              </td>

  </tr>

  <tr>

    <td style="width: 9.07%; vertical-align: middle;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#a52262995ex99_2.htm">99.2</a></div>
              </td>

    <td style="width: 1%; vertical-align: middle;" colspan="1">&#160;</td>

    <td style="width: 90%; vertical-align: middle;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#a52262995ex99_2.htm">Presentation Slide
                    Deck, furnished hereto.</a></div>
              </td>

  </tr>


</table>
        <div> <br />
        </div>

        <div> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        </div>

        <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;"> <br />
        </div>

        <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">SIGNATURE</div>

        <div>&#160;</div>

        <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
          undersigned hereunto duly authorized.</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z982a375214ca4b478d0b1cc1a30dc66f">


  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td colspan="2" style="vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Scholar Rock Holding Corporation</div>
              </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 47%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 47%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Date: August 7, 2020</div>
              </td>

    <td style="width: 3%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">By:</div>
              </td>

    <td style="width: 47%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-decoration: underline;">/s/ Junlin Ho</span></div>
              </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 47%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Junlin Ho</div>
              </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 47%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Senior Vice President, Head of Legal</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

      </div>

    </div>

  </div>

</body>

<!-- Mirrored from investors.scholarrock.com/node/7531/html by HTTrack Website Copier/3.x [XR&CO'2014], Sat, 21 Dec 2024 12:11:37 GMT -->
</html>
</XBRL>
<div><a name="a52262995ex99_1.htm"></a></div><html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 7.0.1.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
  </div>
  <div> <br>
  </div>
  <div>
    <div class="bw-release">
      <h1 style="text-align: center; list-style-position:inside;FONT-SIZE: 14pt;"> <b>Scholar Rock Reports Second Quarter 2020 Financial Results and Highlights Business Progress</b> </h1>
      <div class="bw-release-subhead">
        <p style="text-align: center; list-style-position:inside;"><b> - <i>On track to report interim efficacy and safety results from TOPAZ Phase 2 clinical trial of SRK-015 in patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA) in 4Q20</i> </b></p>
        <p style="text-align: center; list-style-position:inside;"><b> - <i>Enrollment expected to advance to combination treatment of SRK-181 and an approved anti-PD-(L)1 therapy in Part A of DRAGON Phase 1 clinical trial in 3Q20; update on dose
              escalation expected in 4Q20</i> </b></p>
        <p style="text-align: center; list-style-position:inside;"><b> - <i>Appointed Tony Kingsley as President and CEO and Ted Myles as CFO and Head of Business Operations; highly accomplished leaders with proven track records of growing and advancing
              biopharma companies</i> </b></p>
        <p style="text-align: center; list-style-position:inside;"><b> - <i>Company hosting conference call at 8am ET to discuss financial results and introduce newest members of management</i> </b></p>
      </div>
      <div class="bw-release-body">
        <div class="bw-release-table-js bw-release-story">
          <p>CAMBRIDGE, Mass.--(BUSINESS WIRE)--August 7, 2020--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported
            financial results for the second quarter ended June 30, 2020 and highlighted recent progress and upcoming milestones for its pipeline programs. </p>
          <p> &#8220;I am impressed by the execution of the team, and momentum is rapidly building for our lead clinical programs, SRK-015 in SMA and SRK-181 in immuno-oncology, towards several potential value-creation opportunities in late 2020 and throughout
            2021,&#8221; said Tony Kingsley, President and CEO of Scholar Rock. &#8220;Scholar Rock has an exceptional proprietary platform that has yielded multiple clinical candidates that have the potential to transform the lives of patients living with serious
            diseases, and I look forward to seeing the company continue to drive additional product candidates forward.&#8221; </p>
          <p> <b>Company Updates and Upcoming Milestones</b> </p>
          <p> <b><u>SRK-015 Program for Spinal Muscular Atrophy:</u></b> </p>
          <p> <i>SRK-015 is a highly selective inhibitor of latent myostatin being developed as the potential first muscle-directed therapy for the treatment of SMA.</i> </p>
          <ul style="list-style-type: disc;">
            <li> <b>On Track to Report Interim Efficacy and Safety Data from the TOPAZ Phase 2 Trial in the Fourth Quarter of 2020.</b> The interim efficacy, safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis will include data from 54
              patients who have progressed through at least six months of treatment in the TOPAZ Phase 2 trial. The remaining three patients (one in Cohort 2 and two in Cohort 3) missed three doses of SRK-015 due to COVID-19-related restrictions at their
              trial site, and their 6-month assessments will be excluded from the interim analysis. These patients have resumed dosing and the Company is working closely with the trial site to schedule their next assessments.
              <ul style="list-style-type: circle;">
                <li> To date, one patient (Cohort 1) has discontinued from the trial for reasons unrelated to the study drug and which occurred prior to the COVID-19 pandemic. All remaining 57 patients are continuing in the study. </li>
                <li> As of August 1, 2020:
                  <ul style="list-style-type: square;">
                    <li> 56 of 57 patients have completed the 5-month visit. </li>
                    <li> 54 of 57 patients have completed the 6-month visit for the interim efficacy and safety analysis. </li>
                    <li> Eight of eight patients who have completed the 12-month treatment period have opted into the 12-month extension study. </li>
                  </ul>
                </li>
              </ul>
            </li>
          </ul>
          <div> </div>
          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> With the progress to date for the completion of patient visits towards the interim analysis, Scholar Rock is working closely with the clinical trial sites through the ongoing COVID-19 pandemic to enable access to routine data monitoring
            activities to prepare for the interim analysis. The Company remains on track to report interim efficacy and safety data in the fourth quarter of 2020. Top-line data for the 12-month treatment period are expected in the first half of 2021. There
            may be further impacts on the timing of future doses and assessments for patients in the trial as the effects of the COVID-19 pandemic continue to evolve. </p>
          <p> <b><u>SRK-181 Program for Immuno-Oncology:</u></b> </p>
          <p> <i>SRK-181 is a potent and highly selective inhibitor of latent TGF&#946;1 activation being developed towards an aim of overcoming resistance and meaningfully increasing the number of patients who may benefit from checkpoint inhibitor therapy.</i>
          </p>
          <ul style="list-style-type: disc;">
            <li> <b>Enrollment Advancing in DRAGON Phase 1 Proof-of-Concept Trial with Update on Dose Escalation Expected in the Fourth Quarter of 2020.</b> The DRAGON Phase 1 dose escalation and dose expansion trial is evaluating SRK-181 in patients with
              locally advanced or metastatic solid tumors. Dose escalation in Part A1 of the trial continues to progress, and the Company expects to advance to Part A2 of the trial to evaluate SRK-181 in combination with an approved anti-PD-(L)1 therapy in
              the third quarter of 2020 and to Part B of the trial in the first quarter of 2021. An update on dose escalation of SRK-181 as a single agent as well as in combination with anti-PD-(L)1 therapy is on track for the fourth quarter of 2020.
              Clinical response and safety data are anticipated in 2021. <br>
              <br>
              The two-part DRAGON trial consists of a dose escalation portion (Part A) for SRK-181 as both a single-agent (Part A1) and in combination with an approved anti-PD-(L)1 therapy (Part A2), followed by a dose expansion portion (Part B) evaluating
              SRK-181 in combination with an approved anti-PD-(L)1 therapy in patients with solid tumors exhibiting primary resistance to that anti-PD-(L)1 therapy. Part B will encompass multiple cohorts that are expected to include urothelial carcinoma,
              cutaneous melanoma, non-small cell lung cancer, and other solid tumors. Patients will be administered SRK-181 IV every 3 weeks (Q3W), and additional dosing regimens may be explored in the future. Key objectives of the study include evaluating
              the efficacy, PK, and safety of SRK-181. </li>
          </ul>
          <div> </div>
          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> &#8220;We are encouraged by the high level of engagement of our trial investigators and patients. Patients in our SRK-015 TOPAZ trial are continuing their visits and thus far, we&#8217;ve seen a high rate of enrollment into the 12-month extension study,&#8221;
            said Yung Chyung, M.D., Chief Medical Officer of Scholar Rock. &#8220;We are also pleased with the progress to date enrolling patients in our SRK-181 DRAGON trial, particularly given the backdrop of the ongoing COVID-19 pandemic. Important readouts
            from these trials will provide meaningful insights into the therapeutic potential of our product candidates as well as the power of our drug discovery platform.&#8221; </p>
          <p> <b><u>Executive Leadership Updates:</u></b> </p>
          <ul style="list-style-type: disc;">
            <li> <b>Appointment of Tony Kingsley as President and Chief Executive Officer. </b>In July 2020, Scholar Rock announced that Tony Kingsley was being appointed President and Chief Executive Officer, effective August 1, 2020. Mr. Kingsley
              replaces Nagesh K. Mahanthappa, Ph.D., MBA, who chose to step down after serving in this role since 2012. Mr. Kingsley is a proven leader with a successful track record of driving growth, strategy and all facets of corporate operation. Dr.
              Mahanthappa continues to serve as a scientific advisor to the Company. </li>
            <li> <b>Appointment of Ted Myles as Chief Financial Officer and Head of Business Operations. </b>In July 2020, Scholar Rock announced the appointment of Ted Myles as Chief Financial Officer and Head of Business Operations, bringing more than
              20 years of experience as a senior finance and operations executive with development and commercial stage biopharmaceutical companies. He had previously served on Scholar Rock&#8217;s Board of Directors, including as chair of the audit committee
              and a member of the compensation committee. </li>
          </ul>
          <p> <b>Second Quarter 2020 Financial Results</b> </p>
          <p> For the quarter ended June 30, 2020, net loss was $19.3 million or $0.65 per share compared to a net loss of $12.5 million or $0.48 per share for the quarter ended June 30, 2019. </p>
          <ul style="list-style-type: disc;">
            <li> Revenue was $3.9 million for the quarter ended June 30, 2020 compared to $5.0 million for the quarter ended June 30, 2019. Revenue was related to the Gilead fibrosis-focused collaboration that was executed in December 2018. </li>
            <li> Research and development expense was $17.0 million for the quarter ended June 30, 2020 compared to $13.7 million for the quarter ended June 30, 2019. The increase year-over-year is attributable to the acceptance of a customized antibody
              display library from Specifica, Inc., costs associated with the TOPAZ Phase 2 clinical trial for SRK-015, and higher personnel-related costs. </li>
            <li> General and administrative expense was $6.4 million for the quarter ended June 30, 2020 compared to $4.7 million for the quarter ended June 30, 2019. The increase year-over-year was primarily attributable to increased headcount and
              professional services. </li>
          </ul>
          <div> </div>
          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> As of June 30, 2020, Scholar Rock had cash, cash equivalents, and marketable securities of $141.2 million, which compares to cash, cash equivalents, and marketable securities of $157.4 million as of December 31, 2019. </p>
          <p> <b>Conference Call/Webcast:</b> </p>
          <p> Scholar Rock will host a conference call and audio webcast to discuss the second quarter 2020 financial results today at 8:00 a.m. Eastern Time. To participate in the call, please dial 833-519-1308 (domestic) or 914-800-3874 (international)
            and refer to conference ID: 5627485. A webcast of the call will also be available on the Investors &amp; Media section of the Scholar Rock website at http://investors.scholarrock.com. An archived replay of the webcast will be available on
            Scholar Rock&#8217;s website at: https://scholarrock.com/ for approximately 90 days following the presentation. </p>
          <p> <b>About Scholar Rock</b> </p>
          <p> Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar
            Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia. Scholar Rock&#8217;s
            approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at
            the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its
            focus on biologically validated growth factors may facilitate a more efficient development path. For more information, please visit www.ScholarRock.com or follow Scholar Rock on Twitter (@ScholarRock) and LinkedIn
            (https://www.linkedin.com/company/scholar-rock/). </p>
          <p> Scholar Rock&#174; is a registered trademark of Scholar Rock, Inc. </p>
          <div> </div>
          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> <b>Forward-Looking Statements</b> </p>
          <p> This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar Rock&#8217;s future expectations, plans and prospects,
            including without limitation, Scholar Rock&#8217;s expectations regarding its growth, strategy, progress and timing of its clinical trials for SRK-015, SRK-181, and other product candidates and indication selection and development timing, the ability
            of any product candidate to perform in humans in a manner consistent with nonclinical or preclinical study data, the potential of its proprietary platform, and the impact of COVID-19 on its clinical trials and its business and operations in
            general.<i> </i>The use of words such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;future,&#8221; &#8220;potential,&#8221; or &#8220;continue,&#8221; and other similar expressions are intended to identify
            such forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and
            adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include Scholar Rock&#8217;s ability to provide the financial support, resources and expertise necessary to identify and develop product
            candidates on the expected timeline, the data generated from Scholar Rock&#8217;s nonclinical and preclinical studies and clinical trials, competition from third parties that are developing products for similar uses, Scholar Rock&#8217;s ability to obtain,
            maintain and protect its intellectual property, the success of Scholar Rock&#8217;s current and potential future collaborations, including its collaboration with Gilead, Scholar Rock&#8217;s dependence on third parties for development and manufacture of
            product candidates including to supply any clinical trials, Scholar Rock&#8217;s ability to manage expenses and to obtain additional funding when needed to support its business activities and establish and maintain strategic business alliances and
            new business initiatives, and the impacts of public health pandemics such as COVID-19 on business operations and expectations, as well as those risks more fully discussed in the section entitled "Risk Factors" in Scholar Rock&#8217;s Quarterly Report
            on Form 10-Q for the quarter ended March 31, 2020, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock&#8217;s subsequent filings with the Securities and Exchange Commission. Any forward-looking
            statements represent Scholar Rock&#8217;s views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of the release, and Scholar Rock undertakes no
            duty to update this information unless required by law. </p>
          <div> </div>
          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <table cellspacing="0" id="z10db25099a1944dca4798521e900ac6f" style="margin-bottom: 10.0px;margin-left: 0px; margin-right: auto; font-size: 10pt;">

              <tr>
                <td rowspan="1" style="text-align: center; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;" colspan="17">
                  <p style="text-align: center; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> <b>Scholar Rock Holding Corporation</b> </p>
                </td>
              </tr>
              <tr>
                <td rowspan="1" style="text-align: center; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;" colspan="17">
                  <p style="text-align: center; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> <b>Condensed Consolidated Statements of Operations</b> </p>
                </td>
              </tr>
              <tr>
                <td rowspan="1" style="text-align: center; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;" colspan="17">
                  <p style="text-align: center; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> (unaudited) </p>
                </td>
              </tr>
              <tr>
                <td rowspan="1" style="text-align: center; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;" colspan="17">
                  <p style="text-align: center; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> (in thousands, except share and per share data) </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="text-align: left;vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td rowspan="1" style="text-align: center; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;" colspan="3"><br>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;" colspan="3"><br>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td rowspan="1" style="text-align: center; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;" colspan="3"><br>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;" colspan="3">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="text-align: left;vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td rowspan="1" style="text-align: center; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;" colspan="3"><br>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;" colspan="3"><br>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td rowspan="1" style="text-align: center; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;" colspan="3"><br>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;" colspan="3">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="text-align: left;vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td rowspan="1" style="text-align: center; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;white-space: nowrap;" colspan="7">
                  <p style="text-align: center; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> <b>Three Months Ended June 30</b> </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;text-align: center; list-style-position:inside;">
                  <p style="text-align: center; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td rowspan="1" style="text-align: center; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;white-space: nowrap;" colspan="7">
                  <p style="text-align: center; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> <b>Six Months Ended June 30</b> </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td rowspan="1" colspan="3" style="text-align: center; list-style-position:inside;vertical-align: bottom;border-bottom: solid black 1.0pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position:inside;"> <b>2020</b> </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;text-align: center; list-style-position:inside;">
                  <p style="text-align: center; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td rowspan="1" colspan="3" style="text-align: center; list-style-position:inside;vertical-align: bottom;border-bottom: solid black 1.0pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position:inside;"> <b>2019</b> </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;text-align: center; list-style-position:inside;">
                  <p style="text-align: center; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td rowspan="1" colspan="3" style="text-align: center; list-style-position:inside;vertical-align: bottom;border-bottom: solid black 1.0pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position:inside;"> <b>2020</b> </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;text-align: center; list-style-position:inside;">
                  <p style="text-align: center; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td rowspan="1" colspan="3" style="text-align: center; list-style-position:inside;vertical-align: bottom;border-bottom: solid black 1.0pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position:inside;"> <b>2019</b> </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;" colspan="3"><br>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;" colspan="3"><br>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;" colspan="3"><br>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;" colspan="3">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;">Revenue</td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> $ </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 3,900 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> $ </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 5,039 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> $ </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 8,930 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> $ </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 8,145 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> &#160; </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;" colspan="3"><br>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;" colspan="3"><br>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;" colspan="3"><br>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;" colspan="3">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;">Operating expenses</td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;" colspan="3"><br>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;" colspan="3"><br>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;" colspan="3"><br>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;" colspan="3"><br>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 30.0px;">Research and development</td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 16,997 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 13,715 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 33,899 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 24,454 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> &#160; </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 30.0px;">General and administrative</td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 6,365 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 4,710 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 12,187 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 8,780 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> &#160; </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;">Total operating expenses</td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 23,362 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 18,425 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 46,086 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 33,234 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> &#160; </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;">Loss from operations</td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> (19,462 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> ) </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> (13,386 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> ) </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> (37,156 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> ) </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> (25,089 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> ) </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;">Other income (expense), net</td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 181 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 861 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 805 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 1,809 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> &#160; </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;">Net loss</td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> $ </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> (19,281 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> ) </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> $ </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> (12,525 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> ) </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> $ </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> (36,351 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> ) </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> $ </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> (23,280 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> ) </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;" colspan="3"><br>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;" colspan="3"><br>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;" colspan="3"><br>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;" colspan="3">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="text-align: left;vertical-align: bottom;padding-left: 0.0px;">Net loss per share, basic and diluted</td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> $ </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> (0.65 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> ) </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> $ </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> (0.48 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> ) </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> $ </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> (1.23 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> ) </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> $ </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> (0.90 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> ) </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;" colspan="3"><br>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;" colspan="3"><br>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;" colspan="3"><br>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;" colspan="3">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="text-align: left;vertical-align: bottom;padding-left: 0.0px;">Weighted average common shares outstanding, basic and diluted</td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 29,690,280 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 25,922,833 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 29,608,814 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 25,758,658 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> &#160; </p>
                </td>
              </tr>

          </table>
          <div> </div>
          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <table cellspacing="0" id="z9c09a1a9359546749017b11dbed2c022" style="margin-bottom: 10.0px;margin-left: 0px; margin-right: auto; font-size: 10pt;">

              <tr>
                <td rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;text-align: center; list-style-position:inside;" colspan="7">
                  <p style="text-align: center; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> <b>Scholar Rock Holding Corporation</b> </p>
                </td>
              </tr>
              <tr>
                <td rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;text-align: center; list-style-position:inside;" colspan="7">
                  <p style="text-align: center; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> <b>Condensed Consolidated Balance Sheets </b> </p>
                </td>
              </tr>
              <tr>
                <td rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;text-align: center; list-style-position:inside;" colspan="7">
                  <p style="text-align: center; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> (unaudited) </p>
                </td>
              </tr>
              <tr>
                <td rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;text-align: center; list-style-position:inside;" colspan="7">
                  <p style="text-align: center; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> (in thousands) </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td rowspan="1" colspan="2" style="text-align: center; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: center; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td rowspan="1" colspan="2" style="text-align: center; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td rowspan="1" style="text-align: center; list-style-position:inside;vertical-align: bottom;border-bottom: solid black 1.0pt;padding-left: 0.0px;white-space: nowrap;" colspan="2"><b>June 30, 2020</b></td>
                <td colspan="1" rowspan="1" style="text-align: center; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td rowspan="1" style="text-align: center; list-style-position:inside;vertical-align: bottom;border-bottom: solid black 1.0pt;padding-left: 0.0px;white-space: nowrap;" colspan="2"><b>December 31, 2019</b></td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="text-align: left;vertical-align: bottom;padding-left: 0.0px;"><b>Assets</b></td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;" colspan="2"><br>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;" colspan="2"><br>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 20.0px;">Cash, cash equivalents and marketable securities</td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> $ </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 141,176 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> $ </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 157,448 </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 20.0px;">Other current assets</td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: solid black 1.0pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: solid black 1.0pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 4,011 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: solid black 1.0pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: solid black 1.0pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 27,719 </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 20.0px;">Total current assets</td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 145,187 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 185,167 </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;padding-left: 20.0px;">Other assets</td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: solid black 1.0pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: solid black 1.0pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 11,173 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: solid black 1.0pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: solid black 1.0pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 11,214 </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="text-align: left;vertical-align: top;padding-left: 0.0px;">Total assets</td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> $ </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 156,360 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> $ </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 196,381 </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td rowspan="1" colspan="2" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td rowspan="1" colspan="2" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="text-align: left;vertical-align: bottom;padding-left: 0.0px;"><b>Liabilities and Stockholders' Equity</b></td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td rowspan="1" colspan="2" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td rowspan="1" colspan="2" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 20.0px;">Current liabilities</td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> $ </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 32,567 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> $ </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 32,814 </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;padding-left: 20.0px;">Long-term liabilities</td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 41,619 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 50,666 </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 20.0px;">Total liabilities</td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: solid black 1.0pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: solid black 1.0pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 74,186 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: solid black 1.0pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: solid black 1.0pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 83,480 </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 20.0px;">Total stockholders' equity</td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 82,174 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;border-bottom: solid black 1.0pt;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 112,901 </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="text-align: left;vertical-align: top;padding-left: 0.0px;">Total liabilities and stockholders' equity</td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> $ </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 156,360 </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;padding-left: 0.0px;"><br>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> $ </p>
                </td>
                <td colspan="1" rowspan="1" style="text-align: right; list-style-position:inside;vertical-align: bottom;border-bottom: double black 2.25pt;padding-left: 0.0px;padding-right: 0.0px;">
                  <p style="text-align: right; list-style-position:inside;margin-bottom: 0px; margin-top: 0px;"> 196,381 </p>
                </td>
              </tr>

          </table>
          <p> &#160; </p>
        </div>
        <div class="bw-release-contact">
          <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
          <p> <b>Scholar Rock Contact: </b><br>
            Investors/Media <br>
            Catherine Hu <br>
            chu@scholarrock.com<br>
            917-601-1649 </p>
          <p> <b>Media Contact: </b><br>
            The Yates Network <br>
            Kathryn Morris <br>
            kathryn@theyatesnetwork.com<br>
            914-204-6412 </p>
        </div>
      </div>
    </div>
  </div>
</body>
</html>
<div><a name="a52262995ex99_2.htm"></a></div><html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 7.0.1.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.2</font><br>
  </div>
  <div> <br>
  </div>
  <div style="text-align: center;">
    <title></title>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/3d63b81f7d23917d8aeb78f34ec19d6f-a52262995ex99_2slide1.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;2Q20 Financial Results and Business Progress&#160;&#160;August 7, 2020&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/3d63b81f7d23917d8aeb78f34ec19d6f-a52262995ex99_2slide2.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Disclaimers&#160;&#160;Various statements in this presentation concerning Scholar Rock&#8217;s future expectations, plans
            and prospects, including without limitation, Scholar Rock&#8217;s expectations regarding its strategy, its product candidate selection and development timing, including timing for the initiation of and reporting results from its clinical trials for
            its product candidates, its disease indication selection and timing for such selection, the ability of SRK-015 to affect the treatment of patients suffering from Spinal Muscular Atrophy (SMA) either as a monotherapy or in conjunction with the
            current standard of care, and the ability of SRK-181 to affect the treatment of cancer patients in a manner consistent with preclinical data constitute forward-looking statements for the purposes of the safe harbor provisions under The Private
            Securities Litigation Reform Act of 1995. The use of words such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;future,&#8221; &#8220;potential,&#8221; or &#8220;continue,&#8221; and other similar
            expressions are intended to identify such forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Scholar
            Rock&#8217;s ability to provide the financial support and resources necessary to identify and develop multiple product candidates on the expected timeline, competition from others developing products for similar uses, the preliminary nature of
            interim clinical data, Scholar Rock&#8217;s ability to obtain, maintain and protect its intellectual property, Scholar Rock&#8217;s dependence on third parties for development and manufacture of product candidates including to supply any clinical trials,
            and Scholar Rock&#8217;s ability to manage expenses and to obtain additional funding when needed to support its business activities and establish and maintain strategic business alliances and new business initiatives as well as those risks more fully
            discussed in the section entitled "Risk Factors" in the Quarterly Report on Form 10-Q for the quarter ended&#160;June 30, 2020, which is on file with the&#160;Securities and Exchange Commission, as well as discussions of potential risks, uncertainties,
            and other important factors in Scholar Rock&#8217;s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock&#8217;s views only as of today and should not be relied upon as representing its views
            as of any subsequent date. Scholar Rock explicitly disclaims any obligation to update any forward-looking statements unless required by law. &#160;&#160;&#169; Scholar Rock, Inc. All rights reserved. August 2020. &#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/3d63b81f7d23917d8aeb78f34ec19d6f-a52262995ex99_2slide3.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Newest Members of Highly Experienced Leadership Team&#160;&#160;3&#160;&#160;TONY KINGSLEY, MBAPresident &amp; CEO&#160;&#160;TED
            MYLES, MBACFO &amp; Head of Business Operations&#160;&#160;Joined Scholar Rock&#8217;s Board of Directors in May 2020President &amp; CEO of Taris Bio President &amp; COO of The Medicines CompanyEVP at Biogen, led global commercial operations&#160;&#160;Strategic,
            operational, and commercial leader&#160;&#160;Financial and operational executive&#160;&#160;Served on Scholar Rock&#8217;s Board of Directors for nearly 2 yearsCFO &amp; COO of AMAG Pharmaceuticals, Inc.CFO &amp; COO of Ocata TherapeuticsCFO &amp; Vice President of
            Operations at PrimeraDx, Inc.&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/3d63b81f7d23917d8aeb78f34ec19d6f-a52262995ex99_2slide4.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Proprietary platform has produced multiple programs with significant therapeutic potential&#160;&#160;Two most
            advanced programs, SRK-015 and SRK-181, are advancing quickly and address markets that are well developed and growing&#160;&#160;Multiple programs and multiple anticipated milestones offer near- and long-term value inflection points and strategic
            optionality&#160;&#160;4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/3d63b81f7d23917d8aeb78f34ec19d6f-a52262995ex99_2slide5.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;5&#160;&#160;&#160;&#160;DRAGON Part A2 Initiation&#160;&#160;DRAGON Part B Initiation&#160;&#160;&#160;&#160;Nominate RGMcProduct Candidate&#160;&#160;Gilead
            Fibrosis-focused TGF&#946; Collaboration&#160;&#160;&#160;&#160;&#160;&#160;DRAGON Clinical Response and Safety Data Across Multiple Tumor TypesPart A2 Combo Efficacy and Safety DataPart B &#8211; MelanomaPart B &#8211; NSCLCPart B &#8211; Urothelial CarcinomaPart B &#8211; Other Solid Tumor
            Types&#160;&#160;SRK-015SMA&#160;&#160;SRK-181 Immuno-Oncology and Oncology&#160;&#160;Preclinical / Platform&#160;&#160;&#160;&#160;TOPAZ Topline12M Data(3 Cohorts)&#160;&#160;Potential SRK-015 Phase 3 in SMA&#160;&#160;TOPAZ Interim Analysis(3 Cohorts)&#160;&#160;Differentiated Pipeline with a Series of Anticipated
            Milestones&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TOPAZ 2 Year Extension Data&#160;&#160;Continue to Discover and Advance Preclinical Programs&#160;&#160;Update on Dose Escalation&#160;&#160;Multiple Opportunities for Additional Indications Beyond SMA&#160;&#160;&#160;&#160;Multiple Additional Opportunities: 1) SRK-181 in
            Oncology; 2) Latent TGF&#946;1 Immune Cell in IO; 3) Latent TGF&#946;1 Immune Cell in Oncology&#160;&#160;SRK-015Other Indications&#160;&#160;Gilead Fibrosis collaboration&#160;&#160;&#160;&#160;&#160;&#160;2022 and Beyond&#160;&#160;2021&#160;&#160;Q3&#160;&#160;Q4&#160;&#160;Q3&#160;&#160;Q4&#160;&#160;Q1&#160;&#160;Q2&#160;&#160;2020&#160;&#160;Latent TGF&#946;1 Immune Cell Immuno-Oncology and
            Oncology&#160;&#160;&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/3d63b81f7d23917d8aeb78f34ec19d6f-a52262995ex99_2slide6.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Review of Clinical Programs: SRK-015 and SRK-181&#160;&#160;6&#160;&#160;Yung Chyung, MDChief Medical Officer&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/3d63b81f7d23917d8aeb78f34ec19d6f-a52262995ex99_2slide7.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;SMA Treatment Landscape: The Shifting Focus to Muscle-Directed Therapies&#160;&#160;&#8224;Mean improvement in HFMSE
            score experienced by patients withlater-onset SMA in the Phase 3 CHERISH clinical trial of nusinersen&#160;&#160;HFMSE Score at Month 15&#160;&#160;Mean baseline score&#160;&#160;Mean improvement with nusinersen&#160;&#160;Unmet medical need for functional improvement with
            muscle-directed therapies&#160;&#160;Total Possible HFMSE Score of 66&#160;&#160;&#160;&#160;Muscle function in SMA (human)Hammersmith Functional Motor Scale Expanded (HFMSE)&#160;&#160;&#160;&#160;&#160;&#160;Address SMN deficiency to prevent further motor neuron deterioration &#160;&#160;Act directly on muscle
            with aim to improve motor function &#160;&#160;SMN Upregulator Therapies&#160;&#160;Muscle-Directed Therapies (SRK-015**)&#160;&#160;SMN = survival motor neuron. *Also referred to as SMN correctors. ** SRK-015 is an investigational therapy under development.&#8224;Source: Mercuri
            E, et.al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378:625-635. &#160;&#160;Muscle-directed therapies needed to complement disease-stabilizing benefits of SMN upregulators*&#160;&#160;Overall prevalence of patients
            with SMA 30,000-35,000 in U.S. and Europe&#160;&#160;7&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/3d63b81f7d23917d8aeb78f34ec19d6f-a52262995ex99_2slide8.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#8224;Source: Mercuri E, et.al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl
            J Med. 2018;378:625-635.&#8224; &#8224;Efficacy and safety of risdiplam (RG7916) in patients with Type 2 or non-ambulant Type 3 spinal muscular atrophy (SMA) Roche/PTC Therapeutics&#160;&#160;Nusinersen CHERISH Trial in Later-Onset SMA&#8224;&#160;&#160;In patients with later-onset
            SMA who were age &gt;5 at screening&#8230;Primary benefit of nusinersen - stabilization of motor functionAttainment of &gt;3-point increase - rare (&lt;15% of patients) even with nusinersen treatment&#160;&#160;Later-Onset SMA: High Unmet Need for
            Muscle-Directed Therapy to Complement SMN Upregulator Therapy&#160;&#160;8&#160;&#160;Risdiplam SUNFISH Trial in Later-Onset SMA&#8224;&#8224;&#160;&#160;Low percentage of patients over the age of 5 achieved &#8805;3-point increase on MFM32 scale, even with risdiplam treatmentHFMSE secondary
            endpoint showed a mean 0.58-point improvement over placebo (not statistically significant) &#160;&#160;% of patients with &gt;3 change in MFM32 total at Month 12&#160;&#160;2-5 years&#160;&#160;6-11 years&#160;&#160;12-17 years&#160;&#160;18-25 years&#160;&#160;Change in MFM32 total score&#160;&#160;&#160;&#160;&#160;&#160;Risdiplam
            Placebo&#160;&#160;100806040200&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/3d63b81f7d23917d8aeb78f34ec19d6f-a52262995ex99_2slide9.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Progress on Path Towards Investigating SRK-015&#8217;s Therapeutic Potential in SMA&#160;&#160;Phase 2 TOPAZ interim
            analysis to evaluate efficacy and safety in SMA&#160;&#160;Results anticipated 4Q20&#160;&#160;Strong translational rationale for investigating myostatin blockade in SMA &#160;&#160;&#61692;&#160;&#160;Therapeutic effects in SMA preclinical mouse model&#160;&#160;&#61692;&#160;&#160;Phase 1 trial in adult healthy
            volunteers demonstrated: Initial safetyPK profile supporting every 4-week dosing regimenPD data confirming robust target engagement&#160;&#160;&#61692;&#160;&#160;Phase 2 TOPAZ trial showed: Preliminary PD analysis demonstrates target engagement in patients with
            SMA&#160;&#160;&#61692;&#160;&#160;9&#160;&#160;Sources: Poster presentations at various scientific congresses: Cure SMA Annual Conference (June 2020), MDA Clinical and Scientific Conference (March 2020), World Muscle Society Congress (October 2019).
            https://scholarrock.com/platform/publications/.&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/3d63b81f7d23917d8aeb78f34ec19d6f-a52262995ex99_2slide10.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SRK-015 Phase 2 Trial Design&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Cohort 1&#160;&#160;Cohort 3&#160;&#160;Design&#160;&#160;Patients&#160;&#160;N= 23*; ages
            5-21Open-label, single-arm20 mg/kg SRK-015 IV Q4W12-month treatment period&#160;&#160;Ambulatory Type 3 SMAReceiving treatment with approved SMN upregulator or as monotherapy&#160;&#160;Cohort 2&#160;&#160;N= 15; ages 5-21 Open-label, single-arm20 mg/kg SRK-015 IV
            Q4W12-month treatment period&#160;&#160;Type 2 or non-ambulatory Type 3 SMAReceiving treatment with approved SMN upregulator&#160;&#160;&#160;&#160;N= 20; ages &#8805;2Double-blind, randomized (1:1) to 2 mg/kg or 20 mg/kg SRK-015 IV Q4W12-month treatment period&#160;&#160;Type 2 SMA
            Initiated treatment with approved SMN upregulator before age 5&#160;&#160;Primary Objectives&#160;&#160;SafetyMean change from baseline in RHS&#160;&#160;SafetyMean change from baseline in HFMSE&#160;&#160;SafetyMean change from baseline in HFMSE&#160;&#160;HFMSE=Hammersmith Functional Motor
            Scale Expanded; RHS=Revised Hammersmith Scale.*Baseline demographics presented as part of AAN virtual platform (May 2020). https://scholarrock.com/platform/publications/.&#160;&#160;We believe SRK-015 has the potential to be backbone therapy to all SMN
            upregulators &#160;&#160;Interim Efficacy and Safety Results Expected 4Q20; Top-line 12-Month Data 1H21&#160;&#160;10&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/3d63b81f7d23917d8aeb78f34ec19d6f-a52262995ex99_2slide11.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;Each Cohort Represents Important POC Opportunity With Significant Potential&#160;&#160;Cohort 3&#160;&#160;&#160;&#160;Efficacy &#8211;
            Therapeutic Goals&#160;&#160;&#160;&#160;&#160;&#160;Safety Goals&#160;&#160;Efficacy signal enables investigation of SRK-015&#8217;s broader potential&#160;&#160;&#160;&#160;Cohort 1&#160;&#160;RHS: Absolute increase in mean change from baseline&#160;&#160;RHS: Substantial % of patients attain &gt;3-point increase&#160;&#160;Additional
            outcomes: timed motor tests&#160;&#160;No significant safety signals&#160;&#160;&#160;&#160;Broader age rangeAny SMN upregulatorMonotherapy in some settingsAdditional neuromuscular indications&#160;&#160;Cohort 2&#160;&#160;HFMSE: Absolute increase in mean change from baseline&#160;&#160;HFMSE:
            Substantial % of patients attain &gt;3-point increase&#160;&#160;Additional outcomes: RULM, WHO motor developmental milestones &#160;&#160;No significant safety signals&#160;&#160;&#160;&#160;Broader age rangeAny SMN upregulatorAdditional neuromuscular indications&#160;&#160;Cohort 3&#160;&#160;HFMSE:
            Substantial improvement in mean change from baseline&#160;&#160;Explore potential differentiation (e.g. timing to onset of therapeutic effect) between high dose and low dose arms&#160;&#160;Additional outcomes: RULM, WHO motor developmental milestones&#160;&#160;No
            significant safety signals&#160;&#160;&#160;&#160;Any SMN upregulatorAdditional early intervention settings (Type 1 and pre-symptomatic)Additional neuromuscular indications&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;11&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/3d63b81f7d23917d8aeb78f34ec19d6f-a52262995ex99_2slide12.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;SRK-181 Has Potential to Increase Response and Be Backbone Therapy to All Checkpoint Inhibitors
            &#160;&#160;*Source: Company information, Wall Street research, Evaluate Pharma.&#8224;Source: Carretero-Gonzalez A, et al. Oncotarget. 2018;9:8706-8715. Meta-analysis of 12 randomized trials with control arm or adequate safety profile (includes nivolumab,
            pembrolizumab, and atezolizumab),&#160;&#160;Significant Unmet Potential to Increase Response to Checkpoint Inhibitors (CPIs) &#160;&#160;Current Checkpoint Inhibitor Market: $25B+*~20% of patients respond to checkpoint inhibitors&#8224; &#160;&#160;&#160;&#160;&#160;&#160;12&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/3d63b81f7d23917d8aeb78f34ec19d6f-a52262995ex99_2slide13.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Significant Interest in Potential Role of TGF&#946; Inhibition in Immuno-Oncology&#160;&#160;Nature (online), Feb. 14,
            2018.&#160;&#160;&#160;&#160;AuthorsWilly Hugo, Jesse M. Zaretsky, Lu Sun, Douglas B. Johnson, Antoni Ribas, Roger S. Lo&#160;&#160;Volume 165, Issue 1,&#160;24 March 2016, Pages 35-44&#160;&#160;July 24, 2020: https://doi.org/10.1038/ s41571-020-0403-1&#160;&#160;February 2019: &#8220;GSK and Merck
            KGaA, Darmstadt, Germany announce global alliance to jointly develop and commercialise M7824, a novel immunotherapy with potential in multiple difficult-to-treat cancers&#8221;&#8364;300 million upfront and up to &#8364;3.7 billion total&#160;&#160;June 2019: &#8220;Merck to
            Acquire Tilos Therapeutics: Merck Gains Portfolio of Investigational Antibodies Modulating TGF&#946;&#8221;$773 million total potential deal value&#160;&#160;13&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/3d63b81f7d23917d8aeb78f34ec19d6f-a52262995ex99_2slide14.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Cancer Genome Atlas RNAseq analysis of &gt;10,000 samples spanning 33 tumor types*&#160;&#160;*Source: National
            Cancer Institute - Cancer Genome Atlas Program.&#8224;Priti H, et al. Top 10 challenges in cancer immunotherapy. Immunity. 2020 Jan 14:52(1):17-35. https://doi.org/10.1016/j.immuni.2019.12.011.&#160;&#160;Substantial proportion of solid tumors exhibit immune
            exclusion&#8224;&#160;&#160;Broad Potential for TGF&#946; Blockade Across Many Solid Tumors&#160;&#160;&#160;&#160;Human Tumor Analyses Reveal TGF&#946;1 as Most Likely Driver of TGF&#946; Pathway Signaling in Cancers&#160;&#160;14&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/3d63b81f7d23917d8aeb78f34ec19d6f-a52262995ex99_2slide15.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;SRK-181: Unique TGF&#946;1-Selective Approach to Overcoming Checkpoint Inhibitor Resistance&#160;&#160;15&#160;&#160;SRK-181Latent
            TGF&#946;1 Inhibitor&#160;&#160;Inhibits TGF&#946;1 pathway - implicated in CPI resistance&#160;&#160;Highly selective targeting - avoids binding to latent TGF&#946;2 and TGF&#946;3 isoforms&#160;&#160;Aimed at increasing therapeutic window &#8211; potentially avoids toxicities associated with
            non-selective TGF&#946; inhibition&#160;&#160;Therapeutic flexibility&#160;-&#160;pair with any CPI and optimize dosing of each component of combination therapy&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/3d63b81f7d23917d8aeb78f34ec19d6f-a52262995ex99_2slide16.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;SRK-181: Therapeutic Rationale Continues to Strengthen&#160;&#160;EVIDENCE TO DATE&#160;&#160;Increasing evidence implicating
            TGF&#946;1&#8217;s pivotal role in CPI resistance &#160;&#160;TGF&#946;1 implicated in immune excluded tumor phenotype; poor CPI responsesTGF&#946;1 expression and immune exclusion broadly observed across solid tumorsMerck KGaA/GSK&#8217;s bintrasfusp alfa (M7824) showed
            encouraging long-term survival potential in NSCLC*&#160;&#160;SRK-181 evaluated in 3 preclinical syngeneic tumor models aimed at emulating primary resistance to CPI in humansTreatment with SRK-181 combined with CPI led to significant impact on anti-tumor
            responses and survival rates in preclinical models&#8224;&#160;&#160;Nonselective TGF&#946; inhibition associated with significant tox; constrains dosingSRK-181: highly selective inhibitor of latent TGF&#946;1 activation with minimal or no binding to latent TGF&#946;2/3
            isoforms SRK-181 did not lead to cardiac or other toxicities in 4-week GLP nonclinical toxicology studies&#160;&#160;SRK-181: potential for robust blockade of TGF&#946;1 pathway&#160;&#160;Significant anti-tumor efficacy in preclinical tumor models&#160;&#160;*Presented at ASCO
            2020. Bintrasfusp alfa (M7824) is a bifunctional protein comprised of anti-PD-L1 and TGF&#946; trap&#160;&#160;&#8224; Preclinical data published in Science Translational Medicine. Martin CJ, et al. Sci Transl Med. 2020 Mar 25;12(536):eaay8456.
            https://scholarrock.com/platform/publications.&#160;&#160;16&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/3d63b81f7d23917d8aeb78f34ec19d6f-a52262995ex99_2slide17.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;DRAGON Phase 1 POC Trial to Evaluate SRK-181&#8217;s Ability to Overcome Primary Resistance to Checkpoint
            Inhibitors&#160;&#160;Open-label, dose escalation, and dose expansion clinical trialEvaluate the efficacy, safety/tolerability, and PK/PD of SRK-181 in combination with approved anti-PD-(L)1 therapyPatients with locally advanced or metastatic solid
            tumors that exhibit primary resistance to anti-PD(L)1 therapyLack of response characterized as stable or progressive disease following &#8805;3 cycles of anti-PD-(L)1 therapy either alone or in combination with chemotherapy&#160;&#160;NCT04291079 on
            www.clinicaltrials.gov.&#160;&#160;Update on dose escalation expected in 4Q20; clinical response and safety data expected in 2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SRK-181:selective inhibitor of TGF&#946;1 activation &#160;&#160;Part A&#160;&#160;Part A1:SRK-181 as a single agent Modified 3+3 dose
            escalationAssess SRK-181 dose range of 80-2400 mg (avg weight 80kg)Part A2:SRK-181 with approved anti-PD-(L)13+3 dose escalation Treat with same anti-PD-(L)1 as previously given with no response&#160;&#160;Part B&#160;&#160;SRK-181 in combo with approved
            anti-PD-(L)1 therapy4 parallel cohorts &#8211; each will enroll up to 40 patientsTarget indications expected to include NSCLC, urothelial carcinoma, melanoma, amongst other solid tumor typesTreat with same anti-PD-(L)1 as previously given with no
            response&#160;&#160;17&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/3d63b81f7d23917d8aeb78f34ec19d6f-a52262995ex99_2slide18.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;DRAGON Part A: Progressing Quickly to Evaluation of SRK-181 with Anti-PD-(L)1 Therapy &#160;&#160;NCT04291079 on
            www.clinicaltrials.gov.&#160;&#160;SRK-181 with approved anti-PD-(L)13+3 dose escalation Focus on patients with primary resistance to single-agent anti-PD-1 or anti-PD-L1 Treat with same anti-PD-(L)1 as previously given with no response&#160;&#160;Expect to
            advance to Part A2 in 3Q20; update on dose escalation expected in 4Q20&#160;&#160;SRK-181 as a single agent Modified 3+3 dose escalationAssess SRK-181 dose range of 80-2400 mg (avg weight 80kg)&#160;&#160;Safety and PK Data as Single-AgentEnables progression to
            evaluation of combination treatment&#160;&#160;Potential for Early Efficacy SignalsAnti-tumor response from combination treatment in individual patients would be unexpected given prior resistance to anti-PD-(L)1 therapy&#160;&#160;DRAGON Part A1&#160;&#160;DRAGON Part
            A2&#160;&#160;18&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/3d63b81f7d23917d8aeb78f34ec19d6f-a52262995ex99_2slide19.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;DRAGON Part B: Multiple Opportunities for Efficacy Signals&#160;&#160;* Planning to open eligibility to patients
            with history of primary resistance to either pembrolizumab or nivolumabNCT04291079 on www.clinicaltrials.gov.&#160;&#160;Study population focused on patients already shown to have primary resistance to single-agent CPI4 parallel cohorts; each to enroll
            up to 40 patientsNSCLC: SRK-181 + pembrolizumabUrothelial carcinoma: SRK-181 + pembrolizumabMelanoma: SRK-181 + pembrolizumab*Additional tumor types: SRK-181 + anti-PD-(L)1 therapy for which patient experienced primary resistance&#160;&#160;DRAGON Part B
            initiation planned 1Q21; anti-tumor and safety data expected starting in 2021&#160;&#160;Potential for Rapid Path to Proof-of-ConceptAnti-tumor response and safety with combination treatmentResponse in individual patients would be unexpected given prior
            resistance to anti-PD-(L)1 therapyEvaluation of patients with stable or progressive diseaseAbility to evaluate response across multiple tumor typesPatient population with high unmet medical needStrong proof-of-concept signal could support
            efficient registrational path&#160;&#160;DRAGON Part B&#160;&#160;19&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/3d63b81f7d23917d8aeb78f34ec19d6f-a52262995ex99_2slide20.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;20&#160;&#160;2Q20 Financial ResultsTed MylesCFO &amp; Head of Business Operations&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/3d63b81f7d23917d8aeb78f34ec19d6f-a52262995ex99_2slide21.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;21&#160;&#160;2Q20 Financial Update (GAAP)&#160;&#160;Revenues&#160;&#160;Operating Expenses&#160;&#160;Net Loss&#160;&#160;Ended June 30, 2020 with $141M
            in cash, cash equivalents, and marketable securities&#160;&#160;Revenues of $3.9 millionRelated to the Gilead fibrosis-focused collaboration&#160;&#160;R&amp;D expense of $17.0 millionY/Y increase due to acceptance of Specifica, Inc. antibody display library,
            SRK-015 TOPAZ Phase 2 trial, personnel-related costs G&amp;A expense of $6.4 millionY/Y increase due to personnel-related costs and professional services&#160;&#160;$19.3 million or $0.65 per share &#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/3d63b81f7d23917d8aeb78f34ec19d6f-a52262995ex99_2slide22.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;22&#160;&#160;&#160;&#160;DRAGON Part A2 Initiation&#160;&#160;DRAGON Part B Initiation&#160;&#160;&#160;&#160;Nominate RGMcProduct Candidate&#160;&#160;Gilead
            Fibrosis-focused TGF&#946; Collaboration&#160;&#160;&#160;&#160;&#160;&#160;DRAGON Clinical Response and Safety Data Across Multiple Tumor TypesPart A2 Combo Efficacy and Safety DataPart B &#8211; MelanomaPart B &#8211; NSCLCPart B &#8211; Urothelial CarcinomaPart B &#8211; Other Solid Tumor
            Types&#160;&#160;SRK-015SMA&#160;&#160;SRK-181 Immuno-Oncology and Oncology&#160;&#160;Preclinical / Platform&#160;&#160;&#160;&#160;TOPAZ Topline12M Data(3 Cohorts)&#160;&#160;Potential SRK-015 Phase 3 in SMA&#160;&#160;TOPAZ Interim Analysis(3 Cohorts)&#160;&#160;Differentiated Pipeline with a Series of Anticipated
            Milestones&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TOPAZ 2 Year Extension Data&#160;&#160;Continue to Discover and Advance Preclinical Programs&#160;&#160;Update on Dose Escalation&#160;&#160;Multiple Opportunities for Additional Indications Beyond SMA&#160;&#160;&#160;&#160;Multiple Additional Opportunities: 1) SRK-181 in
            Oncology; 2) Latent TGF&#946;1 Immune Cell in IO; 3) Latent TGF&#946;1 Immune Cell in Oncology&#160;&#160;SRK-015Other Indications&#160;&#160;Gilead Fibrosis collaboration&#160;&#160;&#160;&#160;&#160;&#160;2022 and Beyond&#160;&#160;2021&#160;&#160;Q3&#160;&#160;Q4&#160;&#160;Q3&#160;&#160;Q4&#160;&#160;Q1&#160;&#160;Q2&#160;&#160;2020&#160;&#160;Latent TGF&#946;1 Immune Cell Immuno-Oncology and
            Oncology&#160;&#160;&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/3d63b81f7d23917d8aeb78f34ec19d6f-a52262995ex99_2slide23.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Appendix&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/3d63b81f7d23917d8aeb78f34ec19d6f-a52262995ex99_2slide24.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;24&#160;&#160;Robust Target Engagement Observed~100-fold increases in serum latent myostatin levels following
            single 20 mg/kg dose in all cohorts of TOPAZConfirms presence of latent myostatin in patients with SMAWell-Behaved, Linear PK Profile Minimal variability across TOPAZ cohortsDose proportional increase in serum drug exposure between low (2
            mg/kg) and high (20 mg/kg) doses&#160;&#160;Preliminary TOPAZ Biomarker Data Provide First Demonstration of Target Engagement in Patients with SMA &#160;&#160;Preliminary PK/PD results include data from 29 patients (12 in Cohort 1, 8 in Cohort 2, and 9 in Cohort
            3).Source: Poster presentation at the MDA Clinical and Scientific Conference (March 2020). https://scholarrock.com/platform/publications/.&#160;&#160;Latent Myostatin Change Over Baseline in SRK-015 TOPAZ Trial&#160;&#160;Latent Myostatin Change Over Baseline in
            Phase 1 HV Trial&#160;&#160;Preliminary TOPAZ Phase 2 Pharmacokinetic (PK) Data&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/3d63b81f7d23917d8aeb78f34ec19d6f-a52262995ex99_2slide25.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;25&#160;&#160;TGF&#946;1 Blockade with SRK-181-mIgG1 Rendered Preclinical Tumor Models Susceptible to Anti-PD1
            Therapy&#160;&#160;Preclinical data published in Science Translational Medicine. Martin CJ, et al. Sci Transl Med. 2020 Mar 25;12(536):eaay8456. https://scholarrock.com/platform/publications.&#160;&#160;Melanoma (Cloudman S91) model: Combination treatment led to
            tumor regression and survival benefitSimilar results in bladder (MBT2) and breast (EMT6) preclinical tumor models &#160;&#160;Anti-PD1/SRK-181-mIgG1 (10 mg/kg QW)&#160;&#160;Anti-PD1/SRK-181-mIgG1 (30 mg/kg QW)&#160;&#160;4/9&#160;&#160;8/11&#160;&#160;SRK-181-mIgG1 (30 mg/kg
            QW)&#160;&#160;3/12&#160;&#160;0/12&#160;&#160;Anti-PD1 (10 mg/kg BIW)&#160;&#160;*P&lt;0.01. &#8224;P&lt;0.05 Log-rank (Mantel-Cox test) vs anti-PD1.&#160;&#160;**&#8224;&#160;&#160;Tumor Regression: Monotherapy&#160;&#160;Tumor Regression: Combination Therapy&#160;&#160;Days after treatment initiation&#160;&#160;Days after treatment
            initiation&#160;&#160;Days after treatment initiation&#160;&#160;Survival Benefit&#160;&#160;Anti-PD1/ SRK-181-mIgG1 led to influx of CD8+ cells in preclinical bladder tumor model&#160;&#160;Anti-PD1&#160;&#160;Overcoming immune exclusion&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/3d63b81f7d23917d8aeb78f34ec19d6f-a52262995ex99_2slide26.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;TGF&#946;1 Isoform Specificity of SRK-181 Improved Preclinical Toxicity Profile&#160;&#160;Preclinical data published
            in Science Translational Medicine. Martin CJ, et al. Sci Transl Med 2020 Mar 25;12(536): eaay8456. *Source: Anderton MJ, et al. Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol Pathol. 2011;39: 916-924.; and Stauber
            AJ, et al. Nonclinical safety evaluation of a transforming growth factor &#946; Receptor I kinase inhibitor in Fischer 344 rats and beagle dogs. J Clin Pract. 2014: 4:3.&#160;&#160;Selectivity of SRK-181 offers potential to overcome toxicity and dose-limiting
            challenges of non-selective TGF&#946; pathway approaches &#160;&#160;Microscopic observations in heart&#160;&#160;Valvulopathy&#160;&#160;Atrium&#8212;Mixed cell infiltrate&#160;&#160;Myocardium&#8212;Degeneration/necrosis&#160;&#160;Myocardium&#8212;Hemorrhage&#160;&#160;Myocardium&#8212;Miced cell infiltrate, base&#160;&#160;Coronary
            artery&#8212;Necrosis with inflammation&#160;&#160;Cardiomyocyte&#8212;Necrosis/inflammatory cell infiltrate&#160;&#160;Control&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Vehicle&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;iv, qwk x 4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;LY2109761&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;300
            mg/kg&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;po, qd x 8&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;PanTGF&#946;Ab&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;30 mg/kg&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;po, qd x 8&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;10
            mg/kg&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;iv, qwk x 4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;30 mg/kg&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;iv, qwk x 4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;100 mg/kg&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;iv, qwk x
            4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SRK-181&#160;&#160;LEGEND&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;UnremarkableMinimalSlightModerate&#160;&#160;Repeat dose pilot toxicology study in adult female Sprague Dawley rats:Cardiac findings were exhibited
            in animals dosed with a pan-TGF&#946; antibody or LY2109761 (inhibitor of ALK5, common TGF&#946; receptor kinase) as expected based on published data&#8224;No cardiotoxicities (valvulopathy) were noted with SRK-181 NOAEL for SRK-181 was the highest dose
            evaluated of 100 mg/kg QW&#160;&#160;4-week GLP toxicology studies: Rats: NOAEL for SRK-181 was up to highest evaluated dose of 200 mg/kg QWNon-human primates: NOAEL for SRK-181 was up to highest evaluated dose of 300 mg/kg QW &#160;&#160;26&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
  </div>
</body>
</html>


  </div>

  </div>

          <script type="text/javascript">var s_CCSWebHostingAccount = "trcgscholarrock";</script>
        <script type="application/json" data-drupal-selector="drupal-settings-json">{"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/7531\/html","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en","themeUrl":"sites\/g\/files\/knoqqb56236\/themes\/site\/nir_pid2662"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"user":{"uid":0,"permissionsHash":"4506f7b957b4baf2488ee006e9b884f3b49293f46cfb6e03ffbb15fedba12da4"}}</script>
<script src="../../sites/g/files/knoqqb56236/files/js/js_D31miEwayYNfIODJWy2ump8i_gwklTzvOKq4eFgXiKw4996.js?scope=footer&amp;delta=0&amp;language=en&amp;theme=nir_pid2662&amp;include=eJyNjEEKgDAMBD8k9UkhTQMGSiJNRfp7ayuePHjK7jAblQIRnVdnAq8tsy_a2cnRpTKoVSH29YOF5w5__LiDkOlEqJhbN-b4bQGTRYaMh9L2Q9yLpQuf0kIl"></script>
<script src="../../../assets.adobedtm.com/898335afd880/c52ee8aa1e90/launch-5ef258dce664.min.js" crossorigin="anonymous" async integrity="sha384-9QSqHMB+yiy/V4i+d2Au+ydEWbBz4E9DqsE+oYKOnL+kj4XAZGYZxabd0P3OGHkf"></script>

  </body>
</html>
